News
Exopharm (ASX:EX1) is a leader in advancing Genetic Medicines and other exosome-based medicines using exosomes or extracellular vesicles (EVs) as a chassis for improved and non-viral drug-delivery.
Exopharm (ASX:EX1) is pursuing a product pipeline-driven platform strategy. Exosomes can be loaded with a variety of active pharmaceutical ingredients (APIs) and can be targeted to selected cell-types and tissue types, improving the safety-profile of the APIs and providing better treatments. Exosomes can be used to deliver small molecule drugs, mRNA, DNA and other types of APIs.
Exosomes are an alternative means of drug-delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell-penetrating peptides, viral vectors and liposomes.
Exopharm’s exosome technologies solve important needs for the success of exosome medicines – LEAP manufacturing technology, LOAD API loading technologies and EVPS tropism technologies.
Exosome-based medicines could improve the treatment of many chronic or inherited medical conditions.
Exopharm is making its proprietary technologies available to pharmaceutical and biotechnology companies that want to harness exosome-delivery for their own products.
In addition, Exopharm is using its technology platform to enable its own product development programs – each aimed at delivering a transformative medicine for an unmet medical need.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Experts
Value in new medicines and ‘longer strides’
News
Last Orders: What you might have missed on the ASX today
Experts
MoneyTalks: A few more hot picks out of COVID from Canary Capital
Health & Biotech
Exopharm’s LEAP technology a breakthrough in exosome therapeutics
Health & Biotech
Exopharm has just dosed it first patient in a wound-healing study
Health & Biotech
Health Kick Podcast: This biopharma company may be the world’s only exosome-based player
Health & Biotech
How mRNA vaccines could defeat the novel coronavirus
Health & Biotech
Check up: Health sector slips as earning season ends
News
ASX Small Cap Lunch Wrap: ‘Only in America’ edition
Health & Biotech
Canary Capital sees explosive potential in Exopharm
Health & Biotech
Nanoveu says there are other ways to clean your phone from corona, shares fly
Health & Biotech
Are we mortgaging the future as COVID-19 closes clinical trials?
Health & Biotech
Biotech: It’s not a get-rich-quick scheme judging by these HY reports
Health & Biotech
Biotech: Exopharm arouses market over potential to treat erectile dysfunction
News
Health: Is this company onto an alternative to stem cell therapy?
Health & Biotech
Health: New US guidelines on breast cancer may help this ASX biotech
Health & Biotech